fashion -WSS

fashion

author：Wikipedia 2025-09-29 22:49:39 - browse：9

In the center, three researchers examine a DNA helix. Two people stand in the front, one puts an apple into a capsule containing vegetables, the other holds a check list while standing next to a pile of medicines. On the right side, a scientist injects into mitochondria while another takes notes. A person behind the duo looks at a projection of a brain. On the left side, a client looks at a heart projection from a device held by a robot — biotech coverage from STAT — Adobe

When it comes to bringing an experimental drug to market and selling it, Novo Nordisk, the maker of the weight loss drug Wegovy, is tops, according to a new analysis.

But if you want to invent lots of potential drugs that could eventually reach the market, you’d be far better off with Johnson & Johnson, Merck, or AstraZeneca.

The analysis, the 13th edition of the Pharmaceutical Innovation and Invention Index, was produced by the consultancy Idea Pharma and released Thursday at the STAT Breakthrough Summit in San Francisco.

STAT+ Exclusive Story

Already have an account? Log in

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily coverage and analysis of the pharma industry — by subscribing to STAT+.

Already have an account? Log in

Monthly

$39

Totals $468 per year

$39/month Get Started

Totals $468 per year

Starter

$30

for 3 months, then $39/month

$30 for 3 months Get Started

Then $39/month

Annual

$399

Save 15%

$399/year Get Started

Save 15%

11+ Users

Custom

Savings start at 25%!

Request A Quote Request A Quote

Savings start at 25%!

2-10 Users

$300

Annually per user

$300/year Get Started

$300 Annually per user

View All Plans

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Supreme Court strikes down use of affirmative action
Next article： Shingles, which affected Dianne Feinstein, is on the rise

WSS

Hearing on Medicare drug price negotiation gets unusually heated

FDA advisers vote against ALS treatment from BrainStorm

Sudafed saga points to U.S. issues with evaluating older drugs

Intercept Pharmaceuticals sells itself for less than $1 billion

Case for ALS therapy Nurown relies on ‘deficient’ data, FDA finds

Lasker Awards 2023: Winners in biomedical research

entertainment

fashion

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily coverage and analysis of the pharma industry — by subscribing to STAT+.

knowledge

Hollywood unions extend contract negotiations for actors

CDC's new outbreak response network to include Northeastern

Affirmative action in medical school literally saved lives

Senators: Long

The cancer drug shortage isn’t new — and neither are the solutions

Second xenotransplant done with gene

In age of alternative facts, a scholarly course on calling out crap

Ukraine and a new approach to mental health in war

FDA approval of Sarepta Duchenne genetic therapy gives me hope

Hearing on Medicare drug price negotiation gets unusually heated

entertainment

It's been 20 years since Dolly the sheep. Where's my clone?

Biotech stock slump in 2023: awaiting the turnaround

Listen: Who gets the credit for GLP

STAT Virtual Event: How to Increase Diversity in Clinical Trials

How one patient went off dialysis — and others can too

Experts study whether long Covid risk adds up with each reinfection

hotspot

leisure time

focus

hotspot